

Status: Currently Official on 14-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-BF650B81-BA02-44D9-9CCF-276B50147383_1_en-US
DOI: https://doi.org/10.31003/USPNF_M11260_01_01
DOI Ref: om4rq

© 2025 USPC
Do not distribute

Calamine Topical Suspension

» Prepare Calamine Topical Suspension as follows.

Calamine	80 g
Zinc Oxide	80 g
Glycerin	20 mL
Bentonite Magma	250 mL
Calcium Hydroxide Topical Solution, a sufficient quantity to make	1000 mL

Dilute the Bentonite Magma with an equal volume of Calcium Hydroxide Topical Solution. Mix the powders intimately with the Glycerin and about 100 mL of the diluted magma, triturating until a smooth, uniform paste is formed. Gradually incorporate the remainder of the diluted magma. Finally add enough Calcium Hydroxide Topical Solution to make 1000 mL, and shake.

If a more viscous consistency in the Calamine Topical Suspension is desired, the quantity of Bentonite Magma may be increased to not more than 400 mL.

[NOTE—Shake the Calamine Topical Suspension before dispensing.]

Packaging and storage—Preserve in tight containers.

MICROBIAL ENUMERATION TESTS (61). and **TESTS FOR SPECIFIED MICROORGANISMS (62).**—It meets the requirements of the tests for absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CALAMINE TOPICAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 30(2)

Current DocId: GUID-BF650B81-BA02-44D9-9CCF-276B50147383_1_en-US
DOI: https://doi.org/10.31003/USPNF_M11260_01_01
DOI ref: [om4rq](#)